November 22, 2019
Zoetis Inc . (NYSE:ZTS) today announced the acquisition of ZNLabs, a full-service veterinary clinical reference laboratory company with a network of labs across the U.S. This follows Zoetis’ recent acquisition of Phoenix Lab as its entry into reference laboratory services and builds on a strategy to develop a more comprehensive diagnostics offering with enhanced value for veterinarians in the U.S. Financial terms of the transaction are not being disclosed. Founded by veterinarians seeking to revolutionize reference laboratory services for companion animals, ZNLabs is guided by its mission to be “Simple. Friendly. Fair.” The company has differentiated itself by offering a simple test menu and fast results with friendly service and no contracts. ZNLabs operates a “hub” laboratory in Louisville, adjacent to a major logistics provider for fast sample turnaround times, with its “spoke” laboratories in Boise, Chicago, Cincinnati, Dallas, New Orleans and Salt Lake City providing local
...
October 31, 2019
Zoetis Inc . (NYSE:ZTS) today announced the completion of the acquisition of Phoenix Central Laboratory for Veterinarians, Inc. (Phoenix Lab), a full service veterinary reference laboratory company, after fulfilling all closing requirements. With the addition of reference laboratory services, Zoetis now can provide more comprehensive diagnostics products and services as an enhanced value to veterinarians in the U.S. Financial terms of the transaction are not being disclosed. Reference laboratories and point-of-care diagnostic testing are highly synergistic, offering veterinarians a single source for a full spectrum of tests, as well as access to the expertise of Board-certified specialists and pathologists to support test results. Phoenix Lab, founded in 1989 and headquartered near Seattle, serves veterinary clinics in 20 states, primarily in the Pacific Northwest, with complete clinical and anatomic pathology testing as well as microbiology, serology, hematology, chemistry,
...
September 20, 2019
Gives veterinarians a new choice for the treatment of mixed external and internal parasitic infestations Treats and has persistent efficacy against ticks and fleas for one month Treats gastrointestinal nematodes Prevents heartworm disease (Dirofilaria immitis) and lungworm disease (angiostrongylosis) Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted marketing authorisation for Simparica Trio™ (sarolaner/moxidectin/pyrantel) chewable tablets, a once-monthly triple combination antiparasitic medication for dogs with, or at risk from, mixed external and internal parasitic infestations. The granting of the marketing authorisation follows a positive opinion adopted by the Committee for Medicinal Products for Veterinary Use on July 18, 2019. “The approval of Simparica Trio™ provides veterinarians a safe and effective option for the treatment of mixed external and internal parasitic infestations in dogs in the form of a new oral chewable,” said Dr. Domenico
...